Hormonal
GIP receptor agonism enhances inflammation-induced anorexia via the Dorsal Vagal Complex (DVC), while its anti-aversive effects are mediated by parabrachial CGRP neurons, demonstrating that food intake suppression and aversion are dissociable.
Current understanding of GLP-1/GIP drugs often focuses on weight loss. This research suggests these drugs also have a distinct, potent anti-nausea/anti-aversion effect mediated by different brain circuits. This dual-action profile could be leveraged to manage quality of life in patients with chronic inflammatory conditions who suffer from both weight loss and severe food aversion.
GIPR in the dorsal vagal complex were required for the acute anorectic effect of GIPR agonism but not its anti-aversive effect.
Why this rating
Preclinical study using genetic knockout models in mice.
Source
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits
Haley S. Province et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2025
DOI 10.1101/2025.08.12.669936
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →